This study aimed to explore the clinical efficacy of palbociclib, ribociclib, and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) and to identify factors influencing treatment... ...

请注册登录后继续浏览